Navigation Links
NPS Pharmaceuticals Commences Tender Offer for 3.0% Convertible Notes Due 2008
Date:9/6/2007

nformation agent at (212) 269-5550, for banks and brokers, or (888) 644-5854 for others.

Neither the NPS Pharmaceuticals Board of Directors nor any other person makes any recommendation as to whether holders of notes should tender their notes, and no one has been authorized to make such a recommendation. Holders of notes must make their own decisions as to whether to tender their notes, and, if they decide to do so, the principal amount of notes to tender.

This announcement is not an offer to buy or the solicitation of an offer to sell any notes. The tender offer for NPS Pharmaceuticals' 3.0% Convertible Notes due 2008 will be made solely by and subject to the terms and conditions set forth in a Schedule TO (including an offer to purchase, related letter of transmittal and other tender offer documents) that is being filed by NPS Pharmaceuticals today with the Securities and Exchange Commission. The Schedule TO will contain important information and should be read carefully before any decision is made with respect to the tender offer. The offer to purchase, letter of transmittal and other tender offer documents are being delivered to holders of the notes. Once the Schedule TO and other documents are filed with the SEC, they will be available free of charge on the SEC's website at http://www.sec.gov, on NPS Pharmaceuticals' website at http://www.npsp.com or by contacting the NPS Pharmaceuticals Corporate Secretary at (800) 730-3644.

NPS Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of small molecules and recombinant proteins as drugs, primarily for the treatment of metabolic, bone and mineral, and central nervous system disorders. The company has drug candidates in various stages of clinical development. Additional information is available on the company's website, '/>"/>

SOURCE NPS Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Midwest colleges strong contenders for NIH funds
4. Versatile Transfection Reagent Offers Low Toxicity and Consistent Performance
5. Ambion Offers Gene Expression Profiling Service
6. CIO Leadership Series: Snap-Ons Moreno offers lessons in IT transformation
7. In pursuit of capital, be sure to track your private offering
8. Ethics Board site offers welcome contrast to state IT mistakes
9. Visions: Preizler offers insurers perspective on healthcare IT
10. State to offer $850K in high-tech training grants
11. Hewlett-Packard exec offers innovative counsel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 Cynvenio, a cancer ... through the genomic analysis of tumor cells in the ... a web-based cancer decision support application powered by CollabRx, ... Cynvenio’s ClearID™ genomic test, Therapy Finder will provide breast ...
(Date:1/15/2014)... This webinar will focus on EMA and ... in biosimilars. , Regulatory frameworks are evolving many countries ... the complex nature of biopharmaceuticals makes the demonstration of ... challenging. Based on the specific aspects of biosimilar drug ...
(Date:1/15/2014)... (PRWEB) January 15, 2014 Two champions ... continued their sponsorship of an annual competition for middle ... and access to, innovative STEM study. The competition presents ... TEAMS: Tests of Engineering Aptitude, Mathematics, and Sciences ...
(Date:1/15/2014)... 15, 2014 2013 was a banner ... State Technologies®. They saw continued independent research led by ... were awarded a $1 million grant from the Susanne ... and Behavior” a peer reviewed journal, Amy Grant highlighted ...
Breaking Biology Technology:Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3
... Nov. 12 AvidBiotics Corp. announced the issuance ... for generating massive diversity within precisely targeted sites ... is referred to as Diversity Generating Retroelements (DGR) ... States (#7,585,957) and in Europe (#1,173,995). UCLA ...
... Nov. 12 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS) ... and nine months ended September 30, 2009. , During ... BioMS Medical and Eli Lilly and Company (NYSE: LLY) ... commercial rights to dirucotide are returned to BioMS. , ...
... 12 Regado Biosciences, a privately held company leading ... announced that David Mazzo, PhD, CEO and President, will ... Healthcare Conference at the St. Regis Hotel in New ... 1:10pm (EST) on Tuesday, November 17 and will include ...
Cached Biology Technology:AvidBiotics Corp. Granted Key U.S. and European Patents on Unique Protein Modification Platform 2BioMS Medical Announces Third Quarter 2009 Results 2BioMS Medical Announces Third Quarter 2009 Results 3BioMS Medical Announces Third Quarter 2009 Results 4BioMS Medical Announces Third Quarter 2009 Results 5BioMS Medical Announces Third Quarter 2009 Results 6BioMS Medical Announces Third Quarter 2009 Results 7BioMS Medical Announces Third Quarter 2009 Results 8Regado Biosciences to Present at the Lazard Capital Markets 6th Annual Healthcare Conference on November 17, 2009 2
(Date:4/23/2014)... hungry diner ripping open a dinner roll, a fuel ... open a hydrogen molecule. Now researchers have captured a ... halves of its hydrogen feast. The view confirms previous ... catalyst work better for alternative energy uses. , This ... where the hydrogen halves end up in the structure ...
(Date:4/23/2014)... a unique rhythmic sound, recorded for decades in the ... minke whale ( Balaenoptera bonaerensis ). First described and ... it sounded like a duck, the bio-duck sound has ... but its source has remained a mystery, until now. ... deployed acoustic tags on two Antarctic minke whales in ...
(Date:4/23/2014)... in Buenos Aires yesterday, Argentina joins the European ... state. The move strengthens the ties between the ... grants Argentinian scientists access to EMBL,s world-class facilities ... "Ever since its inception, fostering excellent life science ... the core of EMBL,s mission," says EMBL Director ...
Breaking Biology News(10 mins):Halving hydrogen 2Halving hydrogen 3Halving hydrogen 4Scientists identify source of mysterious sound in the Southern Ocean 2Scientists identify source of mysterious sound in the Southern Ocean 3
... of mold and other causes of Sick Building ... with The American Phytopathological Society (APS). , Sick ... which building occupants experience health problems while inside ... with SBS range from allergy attacks and asthma ...
... and taking in nutrients, plant roots secrete a ... roots, as well as insects and microbes. But ... has not been extensively investigated—until now. Using the ... cabbage, Jorge Vivanco and co-workers at Colorado State ...
... earliest cities in northern China starting as far back ... successful rice farming combined with other crops, says University ... associate rice with Chinese agriculture, most archeologists have, until ... most important food associated with northern China. However, recent ...
Cached Biology News:What's really making you sick? Plant pathologists offer the science behind Sick Building Syndrome 2Roots Engage in Underground Chemical Warfare 2
... a user-friendly statistical software package for scientists ... statistical analysis without being a statistical expert.Just ... and research and SigmaStat suggests the appropriate ... tests underlying assumptions and suggests another test ...
... Novexin offers bespoke, cost-effective solutions for complex protein ... extensive expertise and experience to help you develop a ... , , ... , transfer all methodology ...
... is a chemiluminescent signal enhancing reagent ... boost the signal obtained with all ... ChemiLucent™ Plus is derived from a ... complex- or chemiluminescent substrate enhancers, ChemiLucent™ ...
... GeneSpring Workgroup solution is a highly ... mining expression data in a workgroup ... deployed in over 40 leading pharmaceutical, ... worldwide. GeneSpring Workgroup streamlines genomics research ...
Biology Products: